A global phase 2 trial found that giving durvalumab plus chemotherapy before surgery enabled most patients with resectable or borderline resectable non-small-cell lung cancer to have an operation, with encouraging pathological complete response rates and no new safety concerns.
Sure, because nothing says “affordable” like a $12,000 infusion before the surgery you still have to pay for.